Prime Medicine Inc Dossier - Source-backed chat

Prime Medicine Inc

PRMENASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.88

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.99Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $542.3M

Enterprise Value $494.9M

Shares Outstanding 197.5M diluted

Next Earnings Date6 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Prime Medicine is a pioneer in next-generation gene editing, utilizing its proprietary Prime Editing platform to perform precise 'search-and-replace' genomic modifications without causing double-stranded DNA breaks. This mechanism offers a superior safety and versatility profile compared to first-generation CRISPR-Cas9 systems. While the company is pre-commercial and currently burning cash, its strategic pivot to focus on high-value in vivo liver programs (PM577 for Wilson Disease and PM647 for AATD) alongside a potential accelerated BLA filing path for its ex vivo CGD program (PM359) presents a highly asymmetric risk/reward profile. The recent appointment of Svetlana Makhni as CFO strengthens financial execution as the company transitions into a multi-program clinical-stage entity.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.25

Mean target$7.12

High · most bullish analyst$11.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

IND/CTA filings for PM577 or PM647 face unexpected regulatory holds or clinical design delays, pushing back first-in-human data timelines past 2027. The FDA demands additional clinical trial enrollment for PM359 instead of accepting the two-patient proof-of-concept package, significantly increasing R&D costs. Capital constraints force a highly dilutive equity raise in late 2026 as the cash runway nears its end.

Base CaseCentral scenario

The company successfully files and clears IND/CTA applications for both PM577 and PM647 in 2026, transitioning both programs into Phase 1 clinical trials. Regulatory dialogue with the FDA remains constructive, establishing a clear path toward a BLA submission for PM359 in CGD based on existing two-patient proof-of-concept data. Cash runway is managed prudently into 2027, supplemented by potential milestone payments from the Bristol Myers Squibb collaboration or non-dilutive financing.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Prime Editing platform capable of correcting ~90% of known disease-causing mutations with high precision and minimal off-target indels.
Strategic collaboration with Bristol Myers Squibb for ex vivo CAR-T products, providing up to $3.5 billion in potential bio-buck milestones and validating the platform.
Potential accelerated BLA pathway for PM359 in CGD using proof-of-concept data from the first two treated patients.
Strong leadership team bolstered by the appointment of Svetlana Makhni as CFO, bringing over 20 years of biotech finance and investment banking experience.

Key Investment Risks

Pre-commercial stage with zero product revenue and a high cash burn rate ($49.1M net loss in Q1 2026).
Limited cash runway extending only into 2027, presenting near-term financing and dilution risks.
High stock volatility (beta of 2.31) typical of early-stage speculative biotech companies.
Intense competition from established gene-editing peers (e.g., Beam Therapeutics, Intellia Therapeutics, CRISPR Therapeutics) with overlapping pipelines.

Thesis Invalidation Triggers

FDA refusal to accept the two-patient clinical package for PM359 BLA submission, requiring a large-scale trial.
Severe adverse safety events or lack of editing efficacy observed in upcoming clinical trials for PM577 or PM647.
Inability to secure additional financing or strategic partnerships before mid-2026, leading to severe capital distress.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.